GNPX Stock Summary and Trading Ideas (Genprex | NASDAQ:GNPX)

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex trades on the NASDAQ stock market under the symbol GNPX.

As of December 22, 2025, GNPX stock price declined to $2.06 with 102,121 million shares trading.

GNPX has a beta of -0.22, meaning it tends to be less sensitive to market movements. GNPX has a correlation of 0.00 to the broad based SPY ETF.

GNPX has a market cap of $4.68 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GNPX traded as high as $3,880.00 and as low as $2.03.

The top ETF exchange traded funds that GNPX belongs to (by Net Assets): VXF.

GNPX has underperformed the market in the last year with a price return of -95.4% while the SPY ETF gained +18.9%. GNPX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.3% and -38.7%, respectively, while the SPY returned +3.5% and +0.2%, respectively.

GNPX support price is $1.99 and resistance is $2.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNPX shares will trade within this expected range on the day.